Multidimensional analysis of diagnosis and treatment status of chronic hepatitis B
10.3760/cma.j.cn112866-20250611-00121
- VernacularTitle:慢性乙型肝炎诊疗现状的多维度分析
- Author:
Ying TAN
1
;
Bo LI
1
;
Aiqi LU
1
;
Lihua LIN
1
;
Xiaoyuan CHEN
1
;
Jianping LI
1
;
Yujuan GUAN
1
Author Information
1. 广州医科大学附属市八医院肝病中心，广州 510440
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Treatment;
Follow up;
Low-level viremia
- From:
Chinese Journal of Experimental and Clinical Virology
2025;39(4):449-453
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim was to analyze key indicators for the diagnosis and treatment of chronic hepatitis B（CHB），including virus detection rate，standardized treatment rate，and loss to follow-up rate，in order to provide a basis for optimizing diagnosis and treatment plans，improve the diagnosis and treatment level of CHB，and improve patient prognosis.Methods:Patients with CHB admitted to the Guangzhou Eighth People′s Hospital Affiliated to Guangzhou Medical University from January 2024 to January 2025 were enrolled. The datas were collected and organized using Excel. Statistical analysis was conducted using SPSS 26.0 software，with a focus on evaluating core indicators such as virus detection rate，standardized treatment rate，and loss to follow-up rate.Results:The positive rate of hepatitis B surface antigen（HBsAg）in non-specific patients was 28.95%，the antiviral treatment rate in specialized patients was 90.78%，and the standardized antiviral drug conversion treatment rate in low-level viremia（LLV）patients was 61.45%. The standardized antiviral drug conversion treatment rates for high-risk patients with combined kidney/bone injuries were 72.75% and 74.40%，respectively. The overall dropout rate was 10.47%，with a dropout rate of 13.80% for LLV patients.Conclusions:The antiviral treatment coverage rates in CHB patients were over 90%，but in certain groups（such as LLV patients and those with kidney or bone injuries），the standardized treatment rates were still low and loss to follow-up rates were high，suggesting the need to improve HBV screening，treatment for special populations，and patient adherence.
